HCW Biologics Begins First-in-Human Trial for Autoimmunity
HCW Biologics has dosed the first patient in its multi-center, first-in-human Phase 1 trial of HCW9302 (NCT07049328) in alopecia...
Navepegritide Trial Results for Children with Achondroplasia
TransCon CNP (navepegritide) met the primary endpoint in the 52-week, randomized, double-blind ApproaCH trial, delivering a statistically significant increase...
T-Knife Files for Phase 1 Trial of PRAME T-Cell Therapy
No clinical data were disclosed. The update centers on a regulatory filing to begin first-in-human testing and preclinical evidence...
Protara to Present New TARA-002 Data for NMIBC Patients
Protara TherapeuticsProtara Therapeutics will present interim safety and efficacy data from 31 BCG‑naïve patients in Cohort A of the...
Promising RAD101 Brain Imaging Trial Reaches 50% Mark
Early Phase 2b imaging readouts from the first three patients showed selective 18F-RAD101 uptake in brain metastases where MRI...
Acumen Launches New Phase 2 Study for Alzheimer’s Drug
Phase 1 data for sabirnetug (ACU193) showed a favorable safety profile with low overall rates of ARIA-E and evidence...
New First-in-Class Fibromyalgia Drug Tonmya Launches in US
Across two double-blind Phase 3 studies in nearly 1,000 adults with fibromyalgia (RELIEF, n=503; RESILIENT, n=457), TONMYA (cyclobenzaprine HCl...
Zanidatamab’s Breakthrough Phase 3 Results for HER2+ GEA
Both zanidatamab (Ziihera) plus chemotherapy and zanidatamab plus tislelizumab (Tevimbra) and chemotherapy achieved statistically significant, clinically meaningful improvements in...
ORIC-944 Trial: Remarkable Efficacy and Safety Results
Topline efficacy from ORIC’s Phase 1b mCRPC study shows a 55% PSA50 response rate (11/20) with 40% confirmed (8/20),...
Inspira’s New Hyla™ Blood Sensor Completes Clinical Study
Reported accuracy came in at 95% to 99% across measured parameters in Inspira Technologies’ clinical study and ongoing lab...